New! View global litigation for patent families

US3811444A - Bioerodible ocular device - Google Patents

Bioerodible ocular device Download PDF

Info

Publication number
US3811444A
US3811444A US31889172A US3811444A US 3811444 A US3811444 A US 3811444A US 31889172 A US31889172 A US 31889172A US 3811444 A US3811444 A US 3811444A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
drug
ocular
acid
eye
carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
J Heller
R Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants

Abstract

An ocular insert for the continuous controlled administration of a predetermined therapeutically effective dosage of drug to the eye over a prolonged period of time. The insert comprises a drug formulation dispersed through a body of selected hydrophobic polycarboxylic acids which erode in the environment of the eye over a prolonged period of time to dispense the desired amount of drug.

Description

United States Patent 1191 Heller et al. 0

[ BIOERODIBLE OCULAR DEVICE [75] Inventors: Jorge Heller, Palo Alto; Richard W.

Baker, Mountain View, both of Calif.

[73] Assignee: Alza Corporation, Palo Alto, Calif. [22] Filed: Dec. 27, 1972 [21] Appl. No.: 318,891

[52] US. Cl 128/260, 128/272, 128/156 [51] Int. Cl... A61n1 31/00 [58] Field of Search 128/272, 156, 260, 127; 424/19, 22, 365, 33

[56] References Cited UNITED STATES PATENTS 3,143,472 8/1964 Lappas et al. 424/33 3,608,063 9/1971 Banker 424/22 3,629,392 12/1971 Banker 424/22 3,618,604 11/1971 Ness 128/260 2,935,449 5/1960 Bavley 424/312 3,279,996 10/1966 Long, Jr. et a1... 424/19 3,551,556 1211970 Kliment et a1. 424/21 R27,401 6/1972 Wichterle et al.. 128/127 X 3,674,902 7/1972 Kalopissis 424/365 X 3,630,200 12/1971 Higuchi 128/260 3,710,795 l/l973 Higuchi 128/260 3,737,521 6/1973 Born 424/22 a 11 {QM/H1111) W.

v [111 3,811,444 1451 May 21, 19174 OTHER PUBLICATIONS David R. Powell and Gilbert S. Banker; Chemical Modification of Polymeric Film Systems in the Solid State 1: Anhydride Acid Conversion, Journal of Phar- 7 1968, pp. 1,598-l,603.

Primary Examiner-Aldrich F. Medbery Attorney, Agent, or Firm-Thomas E. Ciotti; Edward L. Mandell; Paul L. Sabatine i [5 7] ABSTRACT An ocular insert for the continuous controlled administration of a predetermined therapeutically e'fiective dosage of drug to the eye over a prolonged period of time. The insert comprises a. drug formulation dispersed through a body of selected hydrophobic polycarboxylic acids which erode in the environment of the eye over a prolonged period of time to dispense the desired amount of drug.

11 Claims, 7 Drawing Figures PATENIEBMY 21 m4 3,81 1 ,444

sum 2 or 3 FIG.3

FIG.4

FIG.5

PATENTED HAY 2 1 i974 SHEU 3 0F 3 TEST MEDIUM ph 7.0, 0.|m BUFFER TEST MEDIU M ph8.0,0. |m BUFFER FIG.6

E2 2 55: we; 5:523

FIG.7

ELAPSED T|ME,HOURS BIOERODIBLE OCULAR DEVICE BACKGROUND OF THE INVENTION administration of drug to the eye over a prolonged period of time. Still more particularly, this invention relates to an ocular drug delivery device which bioerodes in the environment of the eye concurrently with the controlled continuous dispensing of drug.

2. The Prior Art 7 It is known to treat diseases of the eye by the repeated periodic application of ophthalmic drugs in glycerinated gelatin lamellae form or more conventionally in liquid or ointment form. While these methods of administration are suitable in many instances, a serious shortcoming is the failure of these types of dosage formulations to dispense the drug in a controlled or continuous manner. Periodic application of these dosage forms, even though they be carried out at intervals during the day and night, results in the eye receiving a massive but unpredictable amount of drug at each time of application. This conventional method of application leads to a surging of drug level to a peak, often surpassing the toxic threshold of the drug, at the time the drug is applied, followed by a rapid decline in drug level, commonly to a level below the critical point needed to achieve the desired therapeutic effect, as tear fluid washes away the drug. This regimen of drug administration is especially disadvantageous for ocular conditions characterized by constant deterioration, i.e., glaucoma, wherein any period without medication is detrimental.

Recognizing these disadvantages of conventional I dosage forms, there have recently been discloseddrug dispensing ocular inserts which, when placed in the environ-ment of the eye, slowly release drugs to the eye for prolonged periods of time. In this regard, see US. Pat. No. 3,416,530 granted Dec. 17, 1968 to Ness entitled Eyeball Medication Dispensing Tablet and US. Pat. No. 3,618,604 granted Nov. 9, 1971 to Ness entitled Ocular Insert.

The ocular inserts disclosed in these patents are fabricated of materials which are biologically inert and insoluble in tear liquid. When such an ocular insert is placed in the upper or lower sac of the eye bounded by the surfaces of the sclera of the eyeball and conjunctiva of the lid it retains its integrity and remains intact, acting as a reservoir to continuously release drug to the eye at a controlled rate. Such devices offer the marked advantage of permitting a controlled and continuous release of drug. However, since they are insoluble in the environment of the eye, they present the problem of requiring removal at the completion of therapy, a procedure which may present difficulty or discomfort to some patients. In rare instances, the removal is made more difficult by unwanted migration of the insert to the upper fornix where it may remain long after the entire drug supply has been released to the eye. Also, such devices have only limited applicability with high molecular weight drugs. These devices generally effect drug release by a diffusion mechanism. It is often difficult or impossible to obtain useful rates of drug release with slowly diffusing high molecular weight drugs.

In pending US. Patent application Ser. No. l79,l29 of Higuchi et al., filed Sept. 9, i971, ocular devices are disclosed which are formed of materials that bioerode in the environment of the eye concurrent with the delivery of' drugs and which thus obviate the problems associated with the removal of ocular insertsfrom the eye.

The choice of erodible materials for use in devices for releasing drugs in the eye has shown to be most difficult. Unlike other areas of the body, such as the gastrointestinal tract, which'is highly durable due to the tough mucosal lining and substantially protected by large flows of highly buffered fluid, and the like, the eye is most easily damaged or at least severely irritated by erosion products.

Acidic erosion products which lower the eye pH below about pH 5.5 can cause serious eye irritation while products yielding pH s below about 4.0 can cause permanent corneal burns. Similarly, erosion products. which cause an ocular tonicity imbalance cause irritation and in many instances clouding of the colloidal gel which makes up the cornea. Many other erosion products such as aromatic fragments, organonitrates and the like can'cause unacceptable degrees of eye irritation. Additionally, the relatively rigid type structure of the eye and the fragile nature of the conjunctival lining of the eye make critical to the selection of material, the property of freedom from crystallinity and abrasiveness. The present invention relates to aclass of bioerodible materials and compositions which operate most advantageously in erodible ocular delivery devicespermitting controlled release of drugs to the eye while producing erosion by-products which are highly'compatible with ocular tissue.

OBJECTS OF THE INVENTION Accordingly, it is a primary object of this invention to provide an improved erodible drug dispensing ocular insert for the controlled and continuous administration of drugs to the eye over a prolonged period of time.

Another object of the invention is to provide animproved material for use in drug dispensing ocular inserts which is capable of bioeroding at controlled rates in the environment of the eye and providing a uniform sustained rate of release of drug in therapeutically effective amounts.

Still another object of this invention is to provide improved materials for use in drug dispensing ocular inserts; which materials bioerode in the environment of the eye at rates dependent upon their chemical composition.

A still further object of this invention is to provide a drug dispensing ocular device formed of an improved bioerodible material which can be adapted to drugs having either relatively high or relatively low solubilities in eye fluids.

These objects, as well as other objects, features and advantages, will become more readily apparent from the following detailed description, the drawings and the accompanying claims.

STATEMENT OF THE INVENTION In accomplishing these objects, a major aspect of this invention resides in an ocularinsert forithe controlled and continuous administration of a predetermined dosage of drug to the eye over a prolonged period of time comprising a. drug formulation confined within a body of bioerodible drug release rate controlling material, the material being hydrophobic poly(carboxylic acid) having, on average, one ionizable carboxylic hydrogen for each 8 to 22 total carbonatoms. These poly (213 ll o wherein: the Rs (R R ,...R") are organic radicals independently selected to impart a hydrophobic character to the polymer and to provide an average of from eight to 22 total carbon atoms for each carboxylic hydrogen.

In another aspect, the present invention resides in an improvement in bioerodible ocular devices for the controlled and continuous administration of a predetermined dosage of drug to the eye wherein the drug is enclosed within a body of bioerodible drug release rate controlling material, said improvement comprising employing as bioerodible drug release rate controlling material a hydrophobic poly(carboxylic acid) having, on average, one carboxylic hydrogen for each eight to 22 total carbon atoms.

One embodiment of this invention resides in an ocular insert for the controlled administration of a conwherein the body continuously meters the flow of a therapeutically effective amount ofdrug to the eye by bioeroding and releasing confined drug at a controlled rate over a prolonged periodof time.

Another embodiment of this invention resides in an ocular insert for the controlled administration'of a predetermined variable dosage of drug to the eye over a prolonged period comprising a layered body of drug release rate controlling material containing variable amounts of drug formulation confined in the separate layers, the body being of an initial shape which is adapted for insertion and retention in the eye and the layers of the body comprising a hydrophobic poly(carboxylic acid) having an average of one carboxylic hydrogen for each eight to 22 total carbon atoms wherein thETYody Eontin uouslynieters the flow ofatherapeifiically effective variable amount of drug to the eye as the layers sequentially bioerode and release at controlled rates over prolonged periods of time the variable amounts of drug formulation which they confine.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a view partlyin front elevation and partly diagrammatic of a human eye illustrating an ocular insert in accord with this invention in an operative position after insertion in the eye.

FIG. 2 is a view partly in vertical section and partly diagrammatic of an eyeball and the upper and lower eyelids associated therewith showing the ocular insert of this invention in operative position.

FIGS. 3, 4 and 5 are diagrammatic cross-sectional views of several embodiments of ocular inserts of this invention.

FIGS. 6 and 7 are graphs illustrating the linearity of drug release attainable with ocular inserts of this invention.

DETAILED DESCRIPTION OF THE INVENTION The term bioerodible, as used in this specification and claims, is defined as the property or characteristic of a body of material to innocuously disintegrate or break down as a unit structure or entity over a prolonged period of time in response to a biological environment in which it is placed. Likewise, the term bioerode is defined as the method by which such disintegration or breakdown occurs.

The terms hydrophobic and hydrophobicity broadly refer to the property of a substance to not absorb or adsorb appreciable amounts of water. As used in this specification and claims, a more precise meaning of these terms is intended; a hydrophobic material is defined as one which absorbs or adsorbs water in a maximum amount not substantially exceeding l0 percent of its dry weight.

In accordance with the present invention there is provided a delivery device for the controlled continuous dispensing of a predetermined dosage of drug to the eye over a prolonged period of time comprising a body of bioerodible drug release rate controlling material containing a drug formulation therein, the material being selected from a certain class of poly(carboxylic acids). These polyacids are characterized as being by drophobic when unionized and compatible with the tissues of the eye and as having a specified proportion of carboxylic hydrogens.

Suitable poly(carboxylic acids) are the hydrophobic polyacids which are represented by the general formula:

I l I c-on C0H vlsrou atoms for each carboxylic hydrogen. Variations of this ratio within this range can vary the erosion and drug release rates of ocular devices prepared from these polymeric acids. Organic radicals represented by R, R ...R" may be selected from hydrocarbon radicals and hetero-atom containing organic radicals. Suitable hetero-atoms for employment in R, R ,...R" can include oxygen, nitrogen, sulfur and phosphorous as well as other hetero-atoms so long as the required hydrophobicity and carbon to carboxylic hydrogen average ratio is maintained. The value of n and hence the average molecular weight of the polymer is not critical and may vary over a wide range. Suitable molecular weights, for example, range from about 10,000 to about 800,000. Materials within this range bioerode to products which may be easily and innocuously passed from the environment of the eye. Preferred molecular weights are from about 15,000 to about 500,000.

While not wishing to limit the scope of the polyacids intended to be employed in accord with this invention,

and while alternative materials and preparative schemes are set forth in the description of suitable polyacids which follows, a preferred method for introducing a carboxylic acid function, as well as other heteroatom functions, into a polymeric material of the type employed in this invention, is to proceed through monomers having a carbon skeleton of at least two car bon atoms. These monomers contain polymerizable olefinic carbon-carbon double bonds. At least a portion of these monomers will have appended thereto one or more carboxyl radicals, or suitable precursors thereof and optionally also other hetero atom radicals. The polymer is formed by effecting addition of these monomers, one to another, across the polymerizable double bonds. This general method for forming polyacids is well known and .does not comprise a part of the present invention. This preparative method may be generally represented by the reaction:

represents a carboxyl group (or carboxyl group precursor)-containing monomer also containing a polymerizable olefinic double bond. Such monomers include, for example, acrylic acid, substituted acrylic acid, maleic acid, maleic anhydride, crotonic acid and the like.

CH and CH represent organic monomers containing a polymerizable double bond which maybe the same or different from l cu This preparative technique can be employed to pretonic acids or by copolymerizing olefmically unsatu-.

rated acids, such as acrylic acid or hydrocarbon- -cn,-c

C-OH

' Pat. No. 2,904,54l issued Sept. 15, 1959.

pare poly(carboxylic acids) in accord with General Formula I having hydrocarbonRs either by polymerizing suitable hydrocarbon substituted olefinicallyunsaturated acids such as substituted acrylic acids and crocarbon Rs include ester groups or Also useful are poly(carboxylic acids) prepared by copolymerizing unsaturated carboxylicacids such as acrylic acid (or substituted acrylic acid) with a polymerizable hydrocarbon. These acids may be represented by the general formula:

u 1%.; Ai -ca e C-OH wherein: R is a hydrocarbon radical, of up to about 12 carbons, or hydrogen; and R is a copolymerized hydrocarbon group. The hydrocarbons which may be copolymerized with unsaturated carboxylic acids include terminally olefinically unsaturated hydrocarbons and olefinically unsaturated hydrocarbons having a conjugated carbon-carbon double bond. Thus typical hydrocarbon groups represented by R p include ethyl, propyl, butyl, isopentyl, and phenylethyl as result when ethylene, propylene, butadiene, isoprene and styrene are, respectively, copolymerized with unsaturated acids. Such preparations are set forth in J. Poly. Sci. 10, 441, (I946 Series) and J. Poly. Sci. I0, 597 (1946 Series).

Poly(carboxylic acids) in accord with General Formula I having hydrocarbon Rs may also be prepared by otherknown techniques, such as for example by oxidizing terminal methyl groups on suitable hydrocarbon polymers to carboxyl groups with alkaline permanganate as described in Cram and Hammond Organic Chemistry, 2nd Ed, p. 525-6; or by carboxylating olefinically unsaturated hydrocarbon polymers by contacting them with carbon monoxide, water and optionally some hydrogen under conditions of elevated temperature and pressure in the presence of strongly acidic catalysts, for example, HF, BF H 80, and the like.

Poly(carboxylic acids) useful in the devices of the invention and illustrated by General Formula I may suitably incorporate oxygen atoms intheir Rs. Oxyhydroether groups. Po.ly(-

carboxylic acids) represented by Formula 1 incorporating ester groups as Rs are especially suitable in devices of this invention. They may be readily prepared by partially esterifying acid polymers or copolymers, which are themselves easily obtained. They offer the advantage of permitting simple variation of the ratio of carbons to acidic ionizable carboxylic hydrogens by varying the extent of partial esterification or the esterifying alcohol employed. As a result easy adjustment of drug release rate and erosion characteristics of the polycarboxylic acid product is obtained.

Asan example of this easy control, poly(acrylic acid) is available commercially or may be easily prepared for example by mixing 167 parts of 60 percent acrylic acid, 232 parts of water, 0.50 parts of potassium peroxydisulfate and 0.25 parts of potassium metabisulfite and heating the mixture to 60C. Po1y(acrylic acid) per so, however, is not a suitable poly(carboxylic acid) for use in devices of this invention as it is substantially hydrophilic and water soluble and does not have the carbon to ionizable hydrogen ratio necessary to give suitable erosion and drug release characteristics in the environment of the eye.

When half the carboxyl groups of poly(acrylic acid) are esterified by reaction with a hexanol, the resulting partial ester is hydrophobic and has a carbon to ionizable hydrogen ratio within the range necessary for materials employed in the devices of this invention (i.e., 12:1). A similarly suitable material would result if twothirds of the poly(acrylic acid) carboxyl groups were esterified with ethanol.

This partial esterification technique is of course not limited to poly(acrylic acid). Any organic lower poly (carboxylic acid) may be partially esterified when necessary to achieve the required hydrophobicity and carbon to acidic hydrogen ratio. Other-polyacids suitable for esterification include homopolymers of unsaturated lower carboxylic acid such as acrylic acid, the lower alkyl acrylic acids, such as methacrylic and ethacrylic acid, crotonic and propiolic acid; maleic acid and fumaric acid: or suitable poly(amino acids) such as poly(-- glutamic acid). Polymers of acid precursors such as poly(maleic anhydride) may be hydrolyzed and partially esterified as well. Also suitable for esterification are acids or precursors copolymerized with lower unsaturated hydrocarbons of from two to eight carbons such as ethylene, propylene, butadiene, styrene and the like, or with lower unsaturated oxyhydrocarbons such as unsaturated ethers of from three to eight carbon atoms. Many of these polymers and copolymers are available commercially. Others can be prepared by bulk, solution, emulsion or suspension polymerization using free radical initiators at 40-100C, all methods well known in the art. The partial esterification may be conveniently effected by contacting the acidcontaining polymers with a controlled quantity of the esterifying alcohol at elevated temperature, optionally in the presence of an acidic esterification catalyst. Alcohols suitable for partially esterifying the above-noted polyacids include the hydrocarbon alcohols, preferably the alkanols of from about one to about 16 carbon atoms, for example methanol, ethanol, isopropanol, n- V three to about 10 carbon atoms such as methyl vinyl ether, ethyl vinyl ether, butyl vinyl ether, hexyl vinyl ether and the like, for example, by the method described in US. Pat. No. 2,927,91 1. Because of the small number of carbon atoms in many of these unsaturated ethers and acids it may be desireable to achieve the required carbon/acidic hydrogen ratio, to terpolymerize these materials with a non-carboxylic hydrogen-containing material, most suitably an unsaturated terpolymerizable unsaturated hydrocarbon of from two to eight carbon atoms such as ethylene, butadiene, or styrene.

The Rs of General Formula 1, as oxyhydrocarbons, may contain alcohol linkages. The employment of alcohol linkage containing oxyhydrocarbons as Rs can pose a problem, however, as the alcohol linkages generally decrease the hydrophobicity of the polyacid, often to below the extent of hydrophobicity required of polyacids for employment in this invention. It is usually possible to incorporate up to about 10 percent, basis total polymer, of alcohollinkage containing Rs in the polyacids.

Nitrogen, sulfur and phosphorous atoms may also be incorporated in R groups employed in the polymers represented by General Formula l. Nitrogen may be present as cyano groups, amide groups or imide groups. Amine groups are generally not suitable as they can result in internal salts being formed between the polymerized acid and amine groups. Sulfur atoms may be present as mercaptan or disulfide linkage while phosphorous atoms may be present as phosphate linkages.

A preferred group of materials from which to fabricate the ocular drug dispensing devices of this invention comprise hydrophobic polymers of an acid selected from acrylic acid, lower alkyl acrylic acids of from four to six carbon atoms per monomeric unit, and maleic acid either alone or copolymerized with up to about 2 moles, per mole of acid, of a copolymerizable olefinically unsaturated group such as ethylene or lower (one to four carbon) alkyl vinyl ethers wherein from about 20 to 90 percent of the acid groups have been esterified with an alkanol of from oneto about 10 carbon atoms and wherein the ratio of total carbon atoms to acidic carboxylic hydrogens is in the range of from about 9:1 to about 20:1.

An even more preferred group of poly(carboxylic acids) comprise the hydrophobic partially esterified copolymers of acrylic acid, methacrylic acid or maleic acid with from 0.2 to 1.5 moles, per mole of acid of ethylene or lower (one to four carbon) alkyl vinyl ether having from about 35 to about percent of their total carboxylic groups esterified with lower alkanol of from about three to about 10 carbon atoms, said copolymers 113% mg; carbon to acidic carboxylichYdFdgEfiiHtioBT from about 10:1 to about 15:1.

A group of poly(carboxylic acids) most preferred for use in accord with the present invention comprise hydrophobic copolymers of maleic acid'with about one mole, per mole of maleic acid, of ethylene or methyl vinyl ether, said copolymer having about half of its total carboxyl groups esterified with a lower monoalkanol of from four to eight carbon atoms, wherein the carbon to acidic carboxylic hydrogen ratio has a value of from about 10:1 to about 14:1.

The poly(carboxylic acids) employed in the devices of this invention are soluble in organic solvents. Accordingly, the polyacids may be conveniently formed or shaped by film casting techniques. An organic solvented solution of the polyacid, optionally containing drug, is prepared and cast or drawn to a film. The solvent is then evaporated to yield a continuous film of the polyacid. The ocular inserts, which are generally in the shape of thin discs and the like, are then punched or cut from this film.

A wide range of organic solvents may be used for the casting solutions. With poly(carboxylic acid) materials having total carbon to carboxylic hydrogen ratios at the lower end of the range specified for this invention, such as ratios in the range of about 8:1 to about 11:1, it is generally preferred to use relatively polar organic solvents, that is, organic solvents having dielectric con stants, as listed in the 51st edition of the Chemical Rub ber Company Handbook of Chemistry and Physics" at' pages 15-62 through E-64, of greater than about 15, for example; lower alkanols such as methanol, ethanol, the propanols, 1 and 2-butano1; lower alkanones such as acetone, diethyl ketone, ethyl methyl ketone and cyclohexanone and halogenated and nitrogenated solvents such as 2-chloroethanol, and nitrobenzene. Poly(carboxylic acids) having higher ratios of total carbon atoms to ionizable hydrogens, such as from 14:1 to 22:1 it is generally preferred to use less polar organic solvents, such as those having dielectric constants of less than about 15, especially less than about 10, for example; ethers such as diethyl ether, isopropyl ether and the like; hydrocarbons such as cyclohexane, benzene and toluene, and other low dielectric materials such as ethyl acetate. With the intermediate ratio poly(carboxylic acids) either group of solvents may be used with the alkanols and alkanones generally being favored.

The casting and drying are carried out at moderate conditions such as at ambient temperature and pressure. Solvent removal may be facilitated by the use of vacuum or slightly elevated temperatures. However, substantially elevated temperatures, such as above 100C for lengthy periods, such as for several hours, may be deleterious to some drugs or poly(carboxylic acids).

It is often desired to incorporate plasticizers in the poly(carboxylic acid) materials to improve or vary their physical properties, such as to make them more flexible. Exemplary plasticizers suitable for employment for the present purpose are the pharmaceutically acceptable plasticizers conventionally used, such as acetyl tri-n-butyl citrate, epoxidized soy bean oil, glycerol monoacetate, polyethylene glycol, propylene glycol diluarate, deconol, dodecanol, 2-ethyl hexanol 2, 2- butoxyethanol and the like. The proportion of optional plasticizer used will vary within broad limits depending upon the characteristics of the poly(carboxylic acid) involved. In general, from about 0.01 parts to about 0.2 parts by weight of plasticizer for each part by weight of the poly(carboxylic acid) can be used. I

When plasticizers are included in the poly(carboxylic acid) materials they are most suitably added prior to shaping the final formed structure, such as by dissolving or dispersing them in the solution from which the film is cast.

The certain poly(carboxylic acids) may be employed in all types of devices for delivering drugs to the eye. While not intending to restrict the scope of this invention, certain embodiments of bioerodible drug releasing devices employing these poly(carboxylic acids) and their use in dispensing drug to the eye are exemplified in the drawings, some of which are exaggerated in size for purposes of illustration.

Referring particularly to F168. 1 and 2, a human eye is shown in each figure, more or less diagrammatically, comprising an eyeball l and upper and lower eyelids 2 and 3, respectively, the eyeball 1 being covered for the greater part of its area by the sclera 4 and at its central portion by the cornea 5. The eyelids 2 and 3 are lined with an epithelial membrane or palpebral conjunctiva.

The sclera 4 is lined with the bulbar conjunctiva which covers the exposed portion of the eyeball. The cornea 5 is covered with an epithelial layer which is transparent. That portion of the palpebral conjunctiva which lines the upper eyelids 2 and the underlying portion of the bulbar conjunctiva defines the upper sac 7 and that portion of the palpebral conjunctiva which lines the lower eyelid 3 and the underlying portion of the bulbar conjunctiva defines the lower sac 11. Upper and lower eyelashes are indicated as 8 and 9, respectively.

A bioerodible ocular insert 12 in accord with this invention is shown in operative position in the lower sac ll of the eye. Other details of the eyeball l are not directly concerned with the structure of the instant invention and are omitted from the Figures in the interest of brevity. To use the ocular insert of the invention, it is inserted in the eye, preferably within the upper sac 7 or lower sac ll, bounded by the surfaces of the sclera of the eyeball and the conjunctiva of the lid. Insertion of the insert l2 into the eye can be satisfactorily accomplished by mounting or grasping the device by means of a suitable holder, which optionally may include a minute suction cup for engaging the outer surface of the insert. The holder may be one of theseveral types commonly used to insert and remove corneal contact lenses, artificial eyes, and the like. Once in place, the ocular insert functions to administer a metered amount of drug from the reservoir to the eye and surrounding tissues over a prolonged period of time. The amount and nature of the products which result when the hydrophobic poly(carboxylic acid) bioerodes are such that they may be innocuously passed from the eye either by discharge through the punctum or by collecting at the junction of the eyelid from where they may be easily periodically removed by wiping, for example.

FIGS. 3 to 5 inclusive, illustrate in diagrammatic cross-sectional views, exemplary types of bioerodible drug dispensing ocular inserts which employ the poly(- carboxylic acids) in accord with this invention. FIG. 3 illustrates generally, by reference numeral 20, an embodiment of this invention wherein the bioerodible ocular insert is comprised ofa continuous matrix 22 fonned of ionizable hydrophobic poly(carboxylic acid) that has particles of drug 21 dispersed therethrough. When ocular device 20 is placed in the environment of the eye, matrix 22 gradually bioerodes and releases drug 21 to the eye and surrounding tissues.

The mechanism by which drug is released by the poly(carboxylic acid) bodied devices of this invention offers distinct advantages.

in general, when a body of erodible material having drug dispersed therethrough is placed in the environment of the eye the following release mechanisms can occur depending upon the nature of the erodible material: if the erodible enclosing material is hydrophilic, it will'absorb tearliquid and swell. Drug can then diffuse out through channels of absorbed tear fluids at rates which are often uneven, unpredictable, difficult to control and highly dependent upon the solubility of the drug in the tear fluids. If the drug is soluble in tear fluids to an extent greater than about 50 parts per million weight, release is rapid and substantially uncontrolled.

If the erodible, enclosing material is hydrophobic but porous, it gives similar diffusion controlled rates, with the same problems. If the enclosing material is hydrophobic and non-porous, as are the certain poly(carboxylic acids) employed in the present invention, the rate of drug release is controlled by the rate at which the enclosing material (matrix 21 in FIG. 3) is eroded or solubilized and enclosed drug (22 in FIG. 3) is uncovered. Such a mechanism offers the advantages of being more easily controlled and of providing a more the result of a' unique mating of equilibriums inherent A in the erosion of these poly(carboxylic acids) with the dynamics of the environment of the eye.

As shown in General Formula I, the poly( carboxylic acids) of this invention may be represented as:

R was R (k 01i OH i i The carboxyl groups are weak acids which, in their unionized form, are hydrophobic. When placed in tear fluid a portion of the carboxyl groups ionize to yield hydrophilic groups and hydronium ions (l-l O As more of the carboxyl groups in an initially hydrophobic polymer chain ionize, the chain assumes an increasingly hydrophilic character and eventually goes into solutionin the tear fluid. This solubilization by ionization occurs only on the outer surfaces of the poly(carboxylic acid bodies). Even if minor amounts of tear fluid do penetrate the surface of the bodies insignificant ionization can occur there since the inner carboxyl groups, being surrounded by an essentially organic medium exhibit a far higher pKa than do the carboxyl groups on the surface which are in a more aqueous medium.

The bioerosion by surface ionization is a reversible reaction,'the equilibrium of which is highly sensitive to pH, and thus, in the environment of the eye, selflimiting. Tear fluids are only weakly alkaline (pH 7.4 7.8), slightly buffered (26 megllHCO of small volume (0.01 cc per eye) and flow 16 percent replacement per minute) and, in the eye, poorly stirred. Under these conditions when hydronium ions are generated, they tend to cluster about the polymer body from which they were generated, lower the pH in the area of the body, and prevent further solubilization by ionization. Some of the clustered hydronium ions gradually disperse or are consumed by the buffers in the tear fluid and are replenished via further ionization. The overall erosion rate which results, with the poly(carboxylic acids) of this invention, is surprisingly slow, perfectly suited for employment in bioerodible ocular devices such as device 20 designed to release drugs over prolonged periods such as periods of from about 8 hours to about 60 days.

The self-limiting pH control inherent with these certain poly(carboxylic acids) offers the further advantage of preventing the pH of the tear fluids from dropping, by reason of excess hydronium ion release, to a level which would be irritating to the tissues of the eye.

The exact rate of erosion is in part dependent upon the chemical makeup of the poly( carboxylic acid). The more hydrophobic the poly acid is, the greater the number of ionized carboxyl groups necessaryto solubilize it and the slower its erosion rate. Thus, by changing the hydrophobicity of the certain polyacids as may be done by varying their ratio of total carbon atoms to ionizable carboxylic hydrogens within the range in accord with this invention, the rate of erosion may be controlled.

The ocular insert as illustrated in H0. 3 can be fabricated in any convenient shape for comfortable retention in the sac of the eye. Thus, the marginal outline of the ocular insert can be ellipsoid, donut-shape, beanshape, banana-shape, circular, rectangular, etc. In cross-section, it can be doubly convex, concavoconvex, rectangular, etc. as the ocular insert in use will tend to conform to the configuration of the eye, the original cross-sectional shape of the device is not of controlling importance. Dimensions of the device can vary widely. The lower limit on the size of the device is governed by the amount of the particular drug to be supplied to the eye and surrounding tissues to elicit the desired pharmacologic response as well as by the smallest sized device which conveniently can be inserted in the eye. The upper limit on the size of the device is governed by the geometric space limitations in the eye, consistent with comfortable retention of the ocular insert, Satisfactory results can be obtained with an ocular device for insertion in the sac of the eye of from 4 to 20 millimeters in length, 1 to 12 millimeters in width, and 0.1 to 2 millimeters in thickness. A preferred pattern of erosion and drug release results when the thickness of the ocular device is substantially smaller than the length or width of the device, preferably the width is less than 10 percent of the length or width. With such a configuration, an essentially constant surface area is presented during erosion. Since erosion rate and drug release rate are proportional to surface area, a constant, or zero order, rate of drug release results. Exemplary shapes of such zero order release devices would be an 8 mm disc and a 6 mm by 12 mm ellipsoid, each punched out of 0.4 mm thick drug-containing poly(carboxylic acid) sheet.

FIG. 4 illustrates, by reference numeral 30, an embodiment of this invention with which a variable rate of drug release may be achieved, wherein the bioerodible ocular insert is comprised of a series of three concentric layers. The outer layer comprises a matrix 22 of ionizable hydrophobic poly(carboxylic acid) of this invention that has particles of drug 21 dispersed therethrough. Matrix 22 erodes and releases drug 21 at a controlled rate over a prolonged period, in the same manner that the matrix in device 20 released drug. When the outer layer comprising matrix 22 and drug 21 has eroded away, middle layer 31 is exposed, and begins to erode. Layer 31 is formed from a bioerodible material, very suitably either the same or different bydrophobic poly(carboxylic acid) employed in matrix 22. Layer 31, as illustrated, contains no drug and thus during the erosion provides a period where no drug would be released. When layer 31 has been eroded the innermost layer is exposed comprising ionizable hydrophobic poly(carboxylic acid) matrix 22a that has particles of drug 21a dispersed therethrough. As matrix 22a erodes, drug 21a is released at a controlled rate for a prolonged period of time. Many variations of the device of FIG. 4 will be apparent to those skilled in the art of drug delivery. For example, a greater number of layers must be employed, a variety of drugs or dosages may be employed in the several layers, or poly acids having different erosion rates may be used in different layers.

FIG. 5 illustrates, by reference numeral 40, an ocular insert embodying this invention which demonstrates how several variables may be manipulated to control the rate and period of drug release. Ocular insert 40 comprises six layers, identified as layers A-F. Layers A-E inclusive each comprise a matrix 22 of hydrophobic poly(carboxylic acid) in accord with the present invention having dispersed therethrough particles of drug 2]. Layer F comprises a slowly eroding poly( carboxylic acid) which contains no drug. The rate of erosion of layer F is slow enough such that it will not be eroded away until after the top'six layershave disappeared. Thus the erosion shall proceed sequentially, with layer A eroding first, layer B eroding second, etc. The thickness, drug loading, expressed in arbitrary units, and the erosion rate expressed in mm of thickness eroded per day, of the particular poly(carboxylic acid) employed in each layer are given in the following Table I.

When device 40 is placed in the environment of the eye, layer A first erodes, releasing 4 units of drug to the eye at a uniform rate for a period of one day. Then layer B erodes. Although the rateof erosion of layer B is half that of layer A, by making layer B half as thick as layer B and by doubling the drug loading of layer B, the same drug release rate and period as was obtained with layer A, is achieved. The same release rate and period is obtained when layer C erodes as it is made thicker and with a lower drug loading to compensate for a faster erosion rate. Layer D, which is the same as layer B except that it is twice as thick, releases drug at the same rate as the prior layers but does so for a two day period instead of for one day. Layer E, identical to layer A except for a doubled drug loadng, releases drug for the same length of time as layer A (I day). but at twice the rate (8 units per day).

Any of the drugs used to treat the eye and surrounding tissues can be incorporated in the ocular insert of this invention. Also, it is practical to use the eye and surrounding tissues as a point. of entry for systemic drugs or antigens that ultimately enter circulation in the blood stream, or enter the nasopharyngeal area by normal routes, and produce a pharmacological response at a site remote from the point of application of the ocular insert. Thus, drug or antigens which will pass through the eye or the tissue surrounding the eye to the blood stream or to the nasal-pharyngeal, esophageal or gastrointestinal areas, but which are not used in therapy of the eye itself, can be incorporated in the ocular insert.

Suitable drugs for use in therapy of the eye with the ocular insert of this invention consistent with their" known dosages and uses are without limitation: antibiotics such as tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamycin, and erythromycin; antibacterials such as sulfonamides, sulfacetamide, sulfamethizole and sulfisoxazole; antivirals including idoxuridine; and other antibacterial agents such as nitrofurazone and sodium propionate', antiallergenics such as antazoline, methapyriline, chlorpheniramine, pyrilamine and prophenpyridamine; anti-inflammatories such as hydrocortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, medrysone, prednisolone, methylprednisolone, predisolone 2l-phosphate, prednisolone acetate, fluoromethalone, betamethasone and triamcinolone; decongestants such as phenylephrine, naphazoline, and tetrahydrazoline; miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide, and demecarium bromide; mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine; and sympathomimetics such as epinephrine.

Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or

non-irritating, pharmacologically acceptable salts such' as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc." For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium salts) can be employed. Furthermore, simple derivatives of the drugs such as ethers, esters, amides, etc., which have desirable characteristics, but which are .easily hydrolized by body pH, enzymes, etc., can be employed.

Ocular devices comprising the hydrophobic poly(- barboxylic acids) of this invention may be used to deliver drugs which'are substantially insoluble in water as well as those which are essentially water-soluble. It is preferred, however, that the drugs employed in the ocular devices of this invention not be highly water soluble. Best results are obtained when the drugs are in a form which is not. soluble in tear fluids to an extent greater than about 20,000 ppm by weight.

in accord with this invention, the ocular insert is intended to provide a complete dosage regimen for eye therapy over this prolonged period. Therefore, the amountofdrug to be incorporated in the device is determined by the fact that sufficient amounts of drug must be present tomaintain the desired dosage level over the therapeutic treatment period. Typically, from 100 micrograms to about 0.05 gram or more of drug is incorporated in the ocular insert. The exact amount of course depends upon the drug used and treatment period. lllustratively, in order to treat glaucoma in an adult human, the daily release dosage should be in the range of between 100 micrograms to 20,000 micrograms of pilocarpine per day. Thus, for example, using pilocarpine with a device intended to remain in place for 7 days, and with a release rate of 500 micrograms of drug per day, 3.5 milligrams of pilocarpine will be incorporated in the device. Other devices containing different-amounts of drug for use for different time periods and releasing drug at higher or lower controlled rates are also readily made by the invention.

Further, in practicing this invention one can employ any of the afore-listed drugs, consistent with their known dosages and uses, to establish an optimum release rate. It has been found, however, that the present continuous mode of administration surprisingly operates to significantly improve the therapeutic efficacy when compared with conventional treatments so that dosages may often be significantly reduced. Exemplary of the dosages to be used with the devices of the present invention are:

Antibiotics, such as polymixin: 200-4000 micrograms/insertlday Antivirals, such as idoxuridene: 100-1000 micrograms/insert/day Anti-inflammatories, such as hydrocortisone acetate 3000-60,000

' micrograms/insert/day or prednisolonc 3000l50,000

The'amount of drug incorporated in devices in accord with this invention can vary considerably depending upon the drug, its dosage, and the length of time the device remains in the eye. Generally, devices may contain up to about 50 percent by weight, basis the poly(- carboxylic acid) of drug, with drug loadings of from about 0.01 to about 40 percent generally being preferred.

To provide compatibility with the eye and surrounding tissues, at least for-the initial period after insertion, the surface of the ocular insert in contact with the eye can be coated with a thin layer, e.g., from 1 to 2 microns thick, of bioerodible hydrophilic material. Exemplary of the suitable materials for this purpose are the water soluble hydrophiiic polymers of vinyl alcohol and vinyl pyrrolidone, gelatin, non-cross-linked polysaccharides, e.g., agar and gum arabic, and the like.

The ocular inserts are suitably packaged using a drug and moisure impermeable packaging material such as the foil-polylaminates, e.g., aluminum foil-polyethylene laminate or aluminum foil-polyester (Mylar)-laminate.

The ocular devices are preferably sterilized prior to insertion in the eye. The sterilization can be effected prior to packaging or after packaging. Suitable sterilization methods such asthe use of heat, radiation or ethylene oxide can be satisfactorily employed. Details for these methods and other are set forth in Remingtons Pharmaceutical Sciences, Vol. XIV, 1970, pp. 1,501-1,518.

The rate' of bioerosion and drug release of materials employed in the invention can be determined experimentally in vitro by testing them under simulated ocular environmental conditions. For example, the rate of ocular bioerosion of a material may be measured by placing a small weighed sample of the material in a 0.026 M HCO; solution of pH about 7.4 (simulated tear fluids) at body temperature (37C), agitating for a timed interval, and periodically measuring the amount of material eroded into the solution. To accurately predict in vivo results, it is necessary to multiply the in vitro rates by an experimentally determined constant which takes into account differences in stirring rate and eye fluid volumes between the eye and the in vitro test apparatus. This constant may be derived by first placing a pluralityof small weighed samples of material in a plurality of eyes and sequentially, over a period of time, removing and weighing the samples. The rate thus determined, divided by the rate of erosion observed in vitro with the same. material, equals the necessary constant.

For a more complete understanding of the nature of this invention, reference should be made to the following examples which are given merely as further illustrations of the invention, and are not to be construed in a limiting sense. All parts are given by weight, unles stated to the contrary.

EXAMPLE 1 v A bioerodible ocular insert employing a hydrophobic poly(carboxylic acid) having on an average from eight to 22 total carbon atoms'for each ionizable acidic carboxylic hydrogen and containing hydrocortisone is prepared in the following manner. 1

A. Preparation of p0ly(carb0xylic acid). 12.6 grams (0.10 equivalents) of ethylene-maleic anhydride copolymer (Monsanto EMA, Grade 31) is stirred with 50 ml (0.4 moles) of n-hexyl alcohol at 120-125C for 7 hours. The solution is cooled to room temperature and methylene chlorideis gradually added to the cloud point. Then more methylene chloride is added to precipitate the product (total vol. 31). The precipitate is' thoroughly leached with the methylene chloride. The solvent is decanted and the product dissolved in 75 ml warm acetone. Methylene chloride is added to the cloud point. Then more methylene chloride is added to precipitate the product (total vol. 21 The precipitate is then thoroughly leached with the methylene chloride. The solvent is decanted and the product dissolved in 75 ml acetone. The solution is transferred to a polypropylene container and solvent is'removed under vacuum at 50C to yield the polymer product. The infrared spectrum of the polymer shows broad bands at 1,680

- and 1,780 cm indicative of ester carboxyl. Titration water absorption and is found to pick up only percent by weight of water. 7

B. Preparation of hydrocurtisone-cntaining ocular insert. 1

1.8 Grams of the half ester polymer of part A is disand is punchcut into desired shapes and sizes. A 6 mm diameter circular disc weighs 7 mg and contains 0.7 mg of hydrocortisone.

C. Testing of inserts. x

A series of 0.3 mm thick ocular inserts prepared in part B are each placed in 60 ml portions of simulated tear fluids (water containing 0.1 moles of K HPO per liter and having a pH of 7.4) and agitated at 37C for 40 minutes. Sequentially the ocular inserts are retrieved, dried and weighed. The samples of simulated tear fluids are analyzed by ultraviolet absorption at 248 millimicrons wave length for hydrocortisone content. The results of these tests indicate that the inserts erode in this solution of simulated tear fluids in 40 minutes at a uniform rate and .that the drug release parallels the erosion. The erosion rate in vitro could be decreased almost 2 orders of magnitude by decreasing the buffer concentration and the rate of stirring. The most reproducible results are obtained at the buffer concentration and rapid stirring rate employed. FIG. 6 illustrates by a graph drug release rates observed when several series of these inserts are tested in vitro.

A series of these ocular inserts are placed in rabbits eyes, where they exhibit a similarly uniform but slower rate of erosion and drug release to that observed in the simulated (in vitro) experiments. About 175+ hours are required for complete erosion. The factor (In vivo)- In vitro) equals 0.01. FIG. 7 illustrates by a graph the linearity of the in vivo drug release as measured by insert weight loss.

During the in vivo test, the rabbits are carefully watched for evidence of ocular irritation. In accordance with the Draize method of measuring ocular irritation, the following conditions are watched for: hyperemia of the lids; hyperemia and chemosis of the conjunctiva; tearing, and exudate from the conjunctiva. The presence or absence of these conditions is indicated by assigning a rating of 0, 1, 2, 3 or 4 to each eye examined for each of these conditions. 0 means no evidence of the condition, 1 means very mild presence of 1 CONTROL EYES (No inserts) Total lrritation Score Type of Number of Observations/ Total Irritation Hour of Observation Mean COnjunctival 1 hyperemia 2/4 0/1 2/5=0.4 Conjunctival chemosis 0/4 0/1 0l5==0 Lid hyperemia 0/4 0/ 1 0/5= Tearing 0/4 0/1 0l5=0 Exudate 0/4 0/1 0/5=0 TOTAL 2/4 0/1 2/5=0.4

TEST EYES (with inserts bf Example 1) Conjunctival hyperemia 40/46 22/28 8/ 17 2/6 0/10 72/l07=0.7 Conjunctival chemosis 6/46 0/28 0/17 0/6 0/10 6/l07=0.1 Lid hyperemia 2/46 14/28 6/17 4/6 12/10 38/l07=0.4 Tearing 0/46 2/28 0/17 0/6 0/10 2/107=0.2 Exudate 20/46 12/28 4/17 0/6 8/10 44/ l 07=0.4

TOTAL 68/46 18/17 6/6 20/10 162/l07=l.5

' Alkanol Example n-butanol 3 n-pentanol 4 n-heptanol 5 I n-octanol The ratio of total carbon atoms to ionizable carbox' ylic hydrogens in each of the resulting half esters is as follows:

Example Ratio: Carbons lonizable Hydrogens 2 l0 3 l l 4 l3 5 l5 6 16 Water absorption tests show the products to be increasingly'hydrophobic, with the product of Example 2 giving the greatest water pick up and the product of Example 6 giving the smallest water pick up.

' Erosion tests under the simultated conditions of Part C of Example 1 are carried out. Constant erosion rates and release rates are noted for each of the materials. The results of these tests, as well as the in vivo results which would be predicted using the factor derived in Part C of Example 1 are as follows:

' Time to Time to Completely 'Erode Completely Erode Example In Vitro, min. In Vivo, hrs.

EXAMPLE 7 A. Preparation of Polymer v A mixture of 5 grams of poly(vinyl methyl ether maleic 'anhydride) 1:1 molar ratio copolymer (GAF Corp. Gantrez AN 169) and 30 ml of n-pentyl alcohol is stirred at C for 16 hours to yield a viscous product/This product is poured into 500 ml of 2% Na,co,

solution. The resulting solution is extracted twice with 400 ml volumes of hexane and acidified to pH l-2 with HCl. The precipitated polymer is collected, washed with slightly acidulated water and dried. The product is found to be the n-pentyl half ester of maleic acid. The product is hydrophobic, exhibiting an equilibrium water pick up of 9 percent by weight. It has an average of 12 carbon atoms for each ionizable carboxylic hydrogen.

B. Preparation of Ocular Inserts A 5 gram portion of the half ester product of part A is dissolved in grams of acetone with stirring. Micronized hydrocortisone (0.5 grams) is added to the syrupy ethanol solution of ester. The hydrocortisone does not dissolve in the ester solution but forms a uniform suspension. The suspension is drawn to a wet thickness of 1 .0 mm. on silicone release paper. The film is dried in moist air at C for 72 hours and stripped from the release paper as a cloudy film having a final dry thickness of 0.3 mm.

Although the film is somewhat brittle, it is easily punch-cut into a variety of shapes suitable for ocular inserts including ellipsoids and 6 mm diameter circles.

C. Testing of Inserts The circular inserts are tested by the methods of Example 1 part C to determine their rate of bioerosion and drug release. In the simulated ocular environment the polymer erodes and releases its drug at a constant rate for about minutes when the final portion of the device dissolves. When placed in rabbit eyes, the same devices require about 20 hours to completely erode.

EXAMPLES 8 13 A. Preparation of Inserts vA series of ocular inserts are prepared using poly(- carboxylic acids) similar to that employed in Example 7. The poly acids employed are the commerciallyavailable half esters of poly( vinyl methyl ether-maleic acid) marketed by GAF Corporation as Gantrez ES- 225 (the ethyl half ester), Gantrez ES-335 l (the isopropyl half ester) and Gantrez ES-425 (the n-butyl half ester).

The ocular insert production method of part B of Example 7 is repeated using these polymers and as drug, hydrocortisone, pilocarpine hydrochloride and chloroamphenicol. Hydrocortisone yields suspensions in I the polymers while chloroamphenicol and pilocarpine dissolve in the polymer at this drug loading (10 percent). The poly(carboxylic acid) drug ocular insert combinations produced in these Examples were as follows:

I Example Time to complete erosion in the eye, hours accesses-bu It should be noted that the rates of erosion of the inserts of Examples 8, 9 and 10 decrease as the hydrophobicity of the polymer increases. Also by comparing the erosion rate of the insert of Example 10 with that of the insert of Example 1 1, it is seen that rate of erosion is independent of drug loading. The rate of release of highly water-soluble pilocarpine hydrochloride is substantially the same with the insert of Example 12 as are the rates of release of less soluble drugs from the inserts of Examples 10 and 13. During the in vivo test of the material of Example 8, some edema is noted as a result of the amount of the acidity generated by the rapid ionization of the polymer. No serious ocular damage is noted, however.

EXAMPLE 14 The preparation of the ocular insert of Example 7 is repeated with one modification. Instead of a 1 mm wet thickness film, a 2 mm wet thickness film is produced which gave a dry film with a thickness of about 0.6 mm. When placed in the simulated ocular environment it requires about 60 minutes to erode.

EXAMPLES l5 17 Average Release Rate Example Plasticizer mg/hour l5 dodecanol 5% l6 *acetal tri n-butyl 5% citrite *Charles Pfizer and Son Brand name Citroflex A4.

EXAMPLE 18 The polymer preparation of Example 7, part A, is repeated with one variation-2-pentanol was substituted for n-pentanol. The rate of esterification is somewhat slower so the reaction is continued for about 60 hours.

The resulting polymer is blended with hydrocortisone and formed into ocular inserts which yield similar erosion and drug release to those observed in Example 7.

EXAMPLE 19 The polymer preparation of Example 7 is repeated employing as esterifying alcohol ml of n-octanol per gram of Gantrez Brand AN 169 methyl vinyl ether maleic anhydride. The reaction period is 22 hours. The half ester is precipitated in a large volume of petroleum ether and then washed.

EXAMPLE 20 The polymer preparation of Example 19 is repeated employing as methyl vinyl ether maleic anhydride polymer a material marketed by GAF Corporation as GantreZ AN 1 19. The Gantrez AN 1 19 is a low molecular weight material having a specific viscosity of 0.1-0.5. The Gantrez AN 169, as employed in Example 19, was a high molecular weight material having a specific viscosity of 2.6-3.5. Four ml of octanol is employed per gram of anhydride. The reaction period is 26 hours. The product does not precipitate from petroleum ether but is separated when the excess n-octanol is evaporated off. I

The product of this Example and the product of Example 19 are tested for water pick-up. Both are hydrophobic.

Inserts are prepared by adding percent (basis polymer) of hydrocortisone acetate to each polymer in ethanol solutions, casting 1.0mm films, drying, and stripping the films and punch-cutting 6 mm diameter circular ocular inserts from the films.

The erosion and drug release rates of these inserts are measured in a sophisticated simultated ocular environment. The inserts are placed in small net bags and suspended in isothermal 37C chambers of circulating synthetic tear fluids, the dissolved polymer and drug content of the tear fluids are continuously monitored by an ultraviolet absorbance technique. The insert made with high molecular weight polymer erodes at a uniform rate over 3 /2 hours. The low molecular weight polymer insert erodes somewhat faster (3 hours to total erosion) but never-the-less at a uniform smooth rate. Drug release follows erosion with both inserts. An earlier experiment has determined the (ln Vivo)/(In Vitro) factor for this new apparatus to be 0.01. Thus, these two inserts would be expected to erode in the eye over periods of about 350 hours and about 300 hours respectively.

EXAMPLE 21 22 A. Preparation of Half Esters of N- Vinyl Pyrrolidine- Maleic Anhydride Copolymers A mixture of 11.6 g (0.118 mole) of maleic anhydride (Aldrich Chemical Co.), 12.7 ml (0.121 mole) of N-vinyl pyrrolidone (Aldrich Chemical Co), 0.12 g bisazodiisobutyronitrile and 140 ml benzene is stirred under dry nitrogen at 60C for 42 hours. The mixture is cooled to room temperature and the product 17.3 g (71 percent) collected by filtration and characterized as follows: mp 260-270C: A KBr max 1,680, 1,780, 1,850 cm; soluble H O, DMF; insoluble CH OH, acetone.

The n-hexyl and n-decyl half esters of the poly N- vinyl pyrrolidone-maleic anhydride copolymer-are prepared according to the procedure for the preparation of the half esters of (methyl vinyl either-maleic anhydride) copolymer given in Part A of Example 7. Both materials are hydrophobic.

B. Production of Inserts Hydrocortisone (10 percent, basis polymer) is added to the polymer and the mixture formed into a viscous solution in acetone. This solution is cast into a 1.0 mm thick film which is dried, recovered and punch-cut into shapes suitable for ocularinserts.

C. Testing The inserts of Part B are tested in the simulated ocular environment described in Example 1. The n-hexyl half ester insert bioerodes and releases drug at a constant rate over a 20-minute period. The n-decyl ester insert bioerodes in about 20+ hours.

EXAMPLE 23 A. Preparation of N-Butyl Acrylate-Methacrylic Acid Copolymer A solution of 14.4 ml (0.10 mole) of n-butyl acrylate, 8.51 ml (0.10 mole) of methacrylic acid, 0.10 g of benzoyl peroxide, and 50 ml of ethanol is stirred under nitrogen at 50 53C for 27 hours. The product is isolated by precipitation into petroleum ether and trimrated with ethyl ether.

B. Preparation of Inserts In a stirred flask, polymer product of part A and 10 percent of hydrocortisone are blended. The mixture is cast and formed into 0.3 mm. thick inserts in accord with the procedures of Example 1 part B.

C. Testing of Inserts The inserts are tested in the simulated ocular enviroment of Example 20 and found to bioerode and deliver drug at a constant rate over a period of minutes.

EXAMPLE 24 A. Preparation of N-Butyl Acrylate-Acrylic Acid Copolymer A solution of 14.4 ml (0.10 mole) of n-butyl acrylate, 6.85 ml (0.10 mole) of acrylic acid, 0.10 g benzoyl peroxide, and 50 ml ethanol is stirred under nitrogen at 48 to 52C for 40 hours. The product is isolated by precipitation into petroleum ether.

B. Insert Production 1n acetone, polymer product of part A and 10 'percent of hydrocortisone are blended. The mixture is cast and formed into inserts in accord with the procedures of Example 1, Part B. The final inserts are 0.3 mm. thick.

C. Testing of Inserts The inserts of Part B are tested in the simulated ocular environment test of Example 1, and found to give a uniform rate of erosion and drug release, eroding over a period of 15 minutes.

EXAMPLES 25 27 Erosion time, minutes Example Hydrocortisone,

' start is completely eroded and The slower erosion of the product of Example 27 is probably due to the large amount of drug interfering with the erosion process.

I EXAMPLE 2s The preparation and simulated environment testing of inserts in accord with Example 24 is repeated substi- 40' percent of its original anhydride groups as esters and the'remaining 60'percent as acids. The product is hytuting 20 percent by weight tetracycline hydrochloride as drug. 12 mm by 7 mm oval inserts 0.3 mm. thick are prepared which give a linear drug release in vitro over a period of 35 minutes at which time they are completely er'oded. v r I f EXAMPLE 29 A. Preparation of Polymer a The preparation of Example 7, part A, is repeated with one modification..lnstead of 30 ml of n-pentyl alcohol, 30 ml of a 50:50 mole mixture of n-pentyl alcohol. and n-hexyl alcohol is used- The resulting ester product is hydrophobic and contains an average 10.5 carbon atoms for each ionizable 'carboxylic hydrogen.

B. Preparation of Inserts Drug-containing ocular inserts are preparedin accord with Part B of Example 7. 1 C. Testing of Inserts a I The inserts are tested by the method of Example 1,

part C. In the simulated ocular environment they give polymer is refluxed in ethanol for 10 hours to yield a viscous product. Analysis shows the product to be-the 'ethyl half ester of styrene-maleic acid copolymer, a

product which is hydrophobic and has an average of 14 drogen.

B. Preparation of Ocular Inserts Ten percent by weight hydrocortisone ocular inserts are prepared by the casting method of Example 7, part drophobic.

B. Preparation of Inserts Ocular inserts containing 10 percent by weight of hydrocortisone acetate are prepared in accord with the method of Example 1.

C. Testing of Inserts The inserts of part B are hydrophobic. When'tested in thesimulated ocular environment test described in Example l, they give an essentially constant rate of drug release over a period of 10 minutes. I

v xAM LE'32 A. Preparation of Polymer The preparation of polymer of Example 1 is repeated with the variation that instead of an excess n-hexanol, 1.2 moles of hexanol per mole of anhydride, is employed. One drop of H 80, is added to catalyze the reactionof the alcohol with the anhydride and cause all thealcohol to react. The resulting product contains 60 percent of its carboxyls as esters and percent as acids. The ratio of total carbon atoms t'ocarboxylic hydrogens is 165:]. I

B. Production of Inserts Ocular inserts containing 10 percent by weight of hydrocortisone acetate are prepared in accord with the method of Example 1.

C. Testing of Inserts I I The inserts of part B are hydrophobic. They erode and releasedrug in the in vitro test of Example 1 part C at a uniform rate over a period of 65 minutes.

EXAMPLES 33 3 4 dride copolymers (Monsanto EMA, Grade 31) are each dissolved in acetone. To one portion is added 20 grams of water and the'mixture is warmed for 4 hours carbon atoms for-each ionizable acidic carboxylic hy- B. Acetone is used as solvent for the casting solution.

The finished'inserts are 0.5 mm thick. g

C. Testing of Inserts The inserts of part Bare tested by the method of Example 1, part C and found to give a linear erosion and drug release.

EXAMPLE 31 1 polymer is employed. After all the added alcohol reacted, 0.2 moles of water is added and the mixture is stirred-until the remaining'anhydride groups have been converted to diacids. The resulting. polymer contains ratio of 3. To the other portion is added 6.2 grams of r absolute methanol. The mixtureis refluxed for l0 hours. Titration analysis indicates that the original maleic anhydride groups are present-in theform'of methyl half esters. Thus thettotal carbo'n)/(carboxy lic hydrogen) ratio is about 7. Prior to preparing drug containing ocular inserts of either of thesematerials, films of the polymers themselves are tested in the simulatedfiocular environment. Both prove to be substantially hydrophillie and to erode essentially.uncontrollably.

What is claimed is: v

l. A bioerodible ocular device for the controlled continuous administration-of drug to the eye comprising a body of bioerodible drug'release rate controlling material shaped and sized with a length of from 4 to 20 mm, a width of from 1 to 12 mm anda thickness of from 0.1 to 2 mm to be retained captive within the sac of the eye and containing a drug dispersed within, the material sented by the formula:

,RI z.. ri

Two 25.2-gram portions of ethylene maleic anhywherein the Rs are organicradicals independently selected to provide an average of from eight to 2 2 total carbon atoms for each carboxylic hydrogen and n has a value providing an average molecular weight of from about 10,000 to about 800,000, which material bioerodes at a controlled rate over a prolonged period of time. in response to the environment of the eye by a process of carboxylic hydrogen ionization, thereby releasing the dispersed drug at a controlled rate over a prolonged period of time.

2. The ocular device defined in claim 1 wherein the Rs are hydrocarbons.

3. The ocular device defined in claim 1 wherein the Rs are oxyhydrocarbons.

4. The ocular device defined in claim 3 wherein the oxyhydrocarbon Rs contain ester groups.

5. The ocular device defined in claim 3 wherein the oxyhydrocarbon Rs contain ether groups.

6. The ocular device defined in claim 3 wherein the drug is an antiinflammatory drug.

7. The ocular device is defined in claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a polymer of an acidselected from the group consisting of maleic acid, acrylic acid and lower alkyl acrylic acids of from four to six carbon atoms, in which from about 20 to about 70 percent of the acid groups have been esterified with an alkanol of from one to about carbon atoms.

8. The ocular device defined in claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a copolymer of an acid selected from the group consisting of maleic acid, acrylic acid, and lower alkyl acrylic acids of from four to about six carbon atoms, with a copolymerizable olefinically unsaturated material selected from the group consisting of ethylene, propylene, butadiene, isoprene and styrene and the lower alkyl vinyl ethers, in which from about 20 to about percent of the acid groups have been esterified with an alkanol of from one to about 10 carbon atoms.

9. The ocular device defined by claim 8 wherein the drug is an antiinflammatory drug.

10. The ocular device defined by claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a hydrophobic partially esterified copolymer of acrylic acid,

methacrylic acid or maleic acid with from 0.2 to 1.5 moles, per mole of acid, of ethylene or lower one to four carbon alkyl vinyl ether having from about 40 to 60 percent of its total carboxyl groups esterified with lower alkanol of from three to 10 carbon atoms.

11. The ocular device defined by claim 10 wherein the drug comprises a drug selected from the group consisting of pilocarpine, hydrocortisone alcohol and acetate and chloroamphenicol.

Claims (10)

  1. 2. The ocular device defined in claim 1 wherein the R''s are hydrocarbons.
  2. 3. The ocular device defined in claim 1 wherein the R''s are oxyhydrocarbons.
  3. 4. The ocular device defined in claim 3 wherein the oxyhydrocarbon R''s contain ester groups.
  4. 5. The oCular device defined in claim 3 wherein the oxyhydrocarbon R''s contain ether groups.
  5. 6. The ocular device defined in claim 3 wherein the drug is an antiinflammatory drug.
  6. 7. The ocular device is defined in claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a polymer of an acid selected from the group consisting of maleic acid, acrylic acid and lower alkyl acrylic acids of from four to six carbon atoms, in which from about 20 to about 70 percent of the acid groups have been esterified with an alkanol of from one to about 10 carbon atoms.
  7. 8. The ocular device defined in claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a copolymer of an acid selected from the group consisting of maleic acid, acrylic acid, and lower alkyl acrylic acids of from four to about six carbon atoms, with a copolymerizable olefinically unsaturated material selected from the group consisting of ethylene, propylene, butadiene, isoprene and styrene and the lower alkyl vinyl ethers, in which from about 20 to about 90 percent of the acid groups have been esterified with an alkanol of from one to about 10 carbon atoms.
  8. 9. The ocular device defined by claim 8 wherein the drug is an antiinflammatory drug.
  9. 10. The ocular device defined by claim 1 wherein the hydrophobic poly(carboxylic acid) comprises a hydrophobic partially esterified copolymer of acrylic acid, methacrylic acid or maleic acid with from 0.2 to 1.5 moles, per mole of acid, of ethylene or lower one to four carbon alkyl vinyl ether having from about 40 to 60 percent of its total carboxyl groups esterified with lower alkanol of from three to 10 carbon atoms.
  10. 11. The ocular device defined by claim 10 wherein the drug comprises a drug selected from the group consisting of pilocarpine, hydrocortisone alcohol and acetate and chloroamphenicol.
US3811444A 1972-12-27 1972-12-27 Bioerodible ocular device Expired - Lifetime US3811444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3811444A US3811444A (en) 1972-12-27 1972-12-27 Bioerodible ocular device

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3811444A US3811444A (en) 1972-12-27 1972-12-27 Bioerodible ocular device
GB5911173A GB1417527A (en) 1972-12-27 1973-12-20 Sustained release dispensing device and method
ES421677A ES421677A1 (en) 1972-12-27 1973-12-20 A dispensing device for dispensing a sustained release active agent.
DK696173A DK144825C (en) 1972-12-27 1973-12-20 Agent in the form of a solid object for sustained release of an active material and method of preparation of the agent
DE19732363963 DE2363963B2 (en) 1972-12-27 1973-12-21
FR7345974A FR2247259B1 (en) 1972-12-27 1973-12-21
CA 188852 CA1046408A (en) 1972-12-27 1973-12-24 Sustained release dispensing device and method
JP481874A JPS613766B2 (en) 1972-12-27 1973-12-27
NL7317731A NL181627C (en) 1972-12-27 1973-12-27 A device for the sustained release of an active substance to an aqueous environment.

Publications (1)

Publication Number Publication Date
US3811444A true US3811444A (en) 1974-05-21

Family

ID=23240002

Family Applications (1)

Application Number Title Priority Date Filing Date
US3811444A Expired - Lifetime US3811444A (en) 1972-12-27 1972-12-27 Bioerodible ocular device

Country Status (1)

Country Link
US (1) US3811444A (en)

Cited By (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4145320A (en) * 1974-10-15 1979-03-20 Paolo Ferruti Polymers containing polyunsaturated acid radicals, process for their preparation and use thereof
FR2407714A1 (en) * 1977-11-07 1979-06-01 Toko Yakuhin Kogyo Kk ophthalmic preparation and process for its manufacture
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4180064A (en) * 1972-12-27 1979-12-25 Alza Corporation System for delivering agent to environment of use over prolonged time
US4228152A (en) * 1974-10-15 1980-10-14 Paolo Ferruti Polymers containing prostaglandin radicals, process for their preparation and use thereof
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4381772A (en) * 1980-11-20 1983-05-03 Guistini Fernando G Bioerodible diaphragm
US4454148A (en) * 1982-09-02 1984-06-12 Merck & Co., Inc. 5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
EP0219207A2 (en) 1985-08-16 1987-04-22 BAUSCH & LOMB INCORPORATED Sustained-release formulation comprising a hydrophobic polymer system
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4685883A (en) * 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
EP0316838A1 (en) * 1987-11-18 1989-05-24 FARMA RESA S.r.l. Tablet for opthalmic use with controlled release of the active substance
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4886870A (en) * 1984-05-21 1989-12-12 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4946929A (en) * 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
EP0431719A1 (en) 1989-10-31 1991-06-12 Columbia Laboratories, Inc. Vaginal tissue moisturizing composition
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US5225196A (en) * 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
US5545409A (en) * 1989-02-22 1996-08-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US20010012847A1 (en) * 1996-11-12 2001-08-09 Lam Andrew C. Methods and devices for providing prolonged drug therapy
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US20030083382A1 (en) * 2001-06-11 2003-05-01 Cundy Kenneth C. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US20030181390A1 (en) * 2001-06-11 2003-09-25 Gallop Mark A. Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20040014940A1 (en) * 2001-06-11 2004-01-22 Raillard Stephen P. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20040037881A1 (en) * 1995-05-22 2004-02-26 Guittard George V. Method for the management of incontinence
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20040254246A1 (en) * 2003-03-31 2004-12-16 Barrett Ronald W. Treating or preventing hot flashes using prodrugs of GABA analogs
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20050090550A1 (en) * 2003-09-11 2005-04-28 Barrett Ronald W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
US20050192353A1 (en) * 2003-09-17 2005-09-01 Barrett Ronald W. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2005110364A2 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050282891A1 (en) * 2004-06-04 2005-12-22 Jia-Ning Xiang Levodopa prodrugs, and compositions and uses thereof
US20060020028A1 (en) * 2004-06-04 2006-01-26 Jia-Ning Xiang Levodopa prodrugs, and compositions and uses thereof
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US20060111325A1 (en) * 2004-11-03 2006-05-25 Gallop Mark A Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US20060111439A1 (en) * 2004-11-03 2006-05-25 Gallop Mark A Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US20060141034A1 (en) * 2004-11-04 2006-06-29 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20060205677A1 (en) * 2005-02-23 2006-09-14 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US20070027210A1 (en) * 2005-06-20 2007-02-01 Noa Zerangue Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
US20070225366A1 (en) * 2005-12-05 2007-09-27 Jia-Ning Xiang Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20080085306A1 (en) * 2006-08-31 2008-04-10 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080118557A1 (en) * 2006-11-17 2008-05-22 Supernus Pharnaceuticals, Inc. Sustained-release formulations of topiramate
US20080146526A1 (en) * 2006-09-15 2008-06-19 Gallop Mark A Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
US20080171789A1 (en) * 2006-12-21 2008-07-17 Jia-Ning Xiang Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20080214663A1 (en) * 2006-12-21 2008-09-04 Jia-Ning Xiang Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
WO2007130663A3 (en) * 2006-05-04 2008-11-13 Herbert Kaufman Method, device, and system for delivery of therapeutic agents to the eye
US20100099761A1 (en) * 2008-10-20 2010-04-22 Xenoport, Inc. Levodopa Prodrug Mesylate Hydrate
US20100099907A1 (en) * 2008-10-20 2010-04-22 Xenoport, Inc. Methods of Synthesizing a Levodopa Ester Prodrug
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2338881A1 (en) 2005-02-23 2011-06-29 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP2402037A1 (en) 2006-05-26 2012-01-04 Pharmacofore, Inc. Controlled release of phenolic opioids
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US9937073B2 (en) 2015-01-20 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US27401A (en) * 1860-03-06 Improvement in solidified fuel from coal-dust
US2935449A (en) * 1958-04-14 1960-05-03 Pfizer & Co C Stabilized vitamin a compositions
US3143472A (en) * 1961-09-25 1964-08-04 Lilly Co Eli Enteric compositions
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3551556A (en) * 1966-01-06 1970-12-29 Ceskoslovenska Akademie Ved Carriers for biologically active substances
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3629392A (en) * 1969-08-15 1971-12-21 Gilbert S Banker Entrapment compositions and processes
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3674902A (en) * 1965-04-15 1972-07-04 Oreal Hair cosmetic compositions containing non-ionic surface active agents
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3737521A (en) * 1970-12-09 1973-06-05 Goodrich Co B F Formulation for sustained release of a biological agent

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US27401A (en) * 1860-03-06 Improvement in solidified fuel from coal-dust
US2935449A (en) * 1958-04-14 1960-05-03 Pfizer & Co C Stabilized vitamin a compositions
US3143472A (en) * 1961-09-25 1964-08-04 Lilly Co Eli Enteric compositions
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3674902A (en) * 1965-04-15 1972-07-04 Oreal Hair cosmetic compositions containing non-ionic surface active agents
US3551556A (en) * 1966-01-06 1970-12-29 Ceskoslovenska Akademie Ved Carriers for biologically active substances
US3618604A (en) * 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US3629392A (en) * 1969-08-15 1971-12-21 Gilbert S Banker Entrapment compositions and processes
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3737521A (en) * 1970-12-09 1973-06-05 Goodrich Co B F Formulation for sustained release of a biological agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. R. Willis, Jr. and Gilbert S. Banker; Polymer Drug Interacted Systems in the Physicochemical Design of Pharmaceutical Dosage Forms I Drug Salts with PVM/MA and with a PVM/MA Hemi Ester , Journal of Pharmaceutical Sciences, Vol. 57, Sept. 1968, pp. 1,598 1,603. *
David R. Powell and Gilbert S. Banker; Chemical Modification of Polymeric Film Systems in the Solid State I: Anhydride Acid Conversion , Journal of Pharmaceutical Sciences, Vol. 58, Nov. 1969, pp. 1,335 1,340. *

Cited By (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180064A (en) * 1972-12-27 1979-12-25 Alza Corporation System for delivering agent to environment of use over prolonged time
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US4228152A (en) * 1974-10-15 1980-10-14 Paolo Ferruti Polymers containing prostaglandin radicals, process for their preparation and use thereof
US4145320A (en) * 1974-10-15 1979-03-20 Paolo Ferruti Polymers containing polyunsaturated acid radicals, process for their preparation and use thereof
US3991759A (en) * 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4116241A (en) * 1976-02-02 1978-09-26 Alza Corporation Osmotic system with laminated wall comprising structurally different semipermeable lamina
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
FR2407714A1 (en) * 1977-11-07 1979-06-01 Toko Yakuhin Kogyo Kk ophthalmic preparation and process for its manufacture
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4381772A (en) * 1980-11-20 1983-05-03 Guistini Fernando G Bioerodible diaphragm
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
US4454148A (en) * 1982-09-02 1984-06-12 Merck & Co., Inc. 5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4946929A (en) * 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4685883A (en) * 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US5225196A (en) * 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4886870A (en) * 1984-05-21 1989-12-12 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
EP0219207A2 (en) 1985-08-16 1987-04-22 BAUSCH & LOMB INCORPORATED Sustained-release formulation comprising a hydrophobic polymer system
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
EP0316838A1 (en) * 1987-11-18 1989-05-24 FARMA RESA S.r.l. Tablet for opthalmic use with controlled release of the active substance
US5629009A (en) * 1989-02-22 1997-05-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5545409A (en) * 1989-02-22 1996-08-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
EP0431719A1 (en) 1989-10-31 1991-06-12 Columbia Laboratories, Inc. Vaginal tissue moisturizing composition
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US8084059B2 (en) 1993-05-27 2011-12-27 Alza Corporation Antidepressant dosage form
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US20040043943A1 (en) * 1995-05-22 2004-03-04 Guittard George V. Method for the management of incontinence
US6919092B2 (en) 1995-05-22 2005-07-19 Alza Corporation Method for the management of incontinence
US20040037881A1 (en) * 1995-05-22 2004-02-26 Guittard George V. Method for the management of incontinence
US20050025832A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050238709A1 (en) * 1996-11-12 2005-10-27 Alza Corporation Methods and devices for providing prolonged drug therapy
US8163798B2 (en) 1996-11-12 2012-04-24 Alza Corporation Methods and devices for providing prolonged drug therapy
US8629179B2 (en) 1996-11-12 2014-01-14 Alza Corporation Methods and devices for providing prolonged drug therapy
US20010012847A1 (en) * 1996-11-12 2001-08-09 Lam Andrew C. Methods and devices for providing prolonged drug therapy
US6930129B2 (en) 1996-11-12 2005-08-16 Alza Corporation Methods and devices for providing prolonged drug therapy
US9000038B2 (en) 1996-11-12 2015-04-07 Alza Corporation Methods and devices for providing prolonged drug therapy
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US9029416B2 (en) 1996-11-12 2015-05-12 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050025831A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US20100093796A1 (en) * 1996-11-12 2010-04-15 Gupta Suneel K Methods and devices for providing prolonged drug therapy
US9144549B2 (en) 1996-11-12 2015-09-29 Alza Corporation Methods and devices for providing prolonged drug therapy
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US6833140B2 (en) 2001-06-11 2004-12-21 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US20040198820A1 (en) * 2001-06-11 2004-10-07 Cundy Kenneth C. Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
US7423169B2 (en) 2001-06-11 2008-09-09 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20080058546A1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20080226716A1 (en) * 2001-06-11 2008-09-18 Xenoport Amino acid conjugates providing for sustained systemic concentration of gaba analogues
US20040014940A1 (en) * 2001-06-11 2004-01-22 Raillard Stephen P. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US20030181390A1 (en) * 2001-06-11 2003-09-25 Gallop Mark A. Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20060287250A1 (en) * 2001-06-11 2006-12-21 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20040254344A1 (en) * 2001-06-11 2004-12-16 Mark Gallop Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US9238616B2 (en) 2001-06-11 2016-01-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7645797B2 (en) 2001-06-11 2010-01-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US20030083382A1 (en) * 2001-06-11 2003-05-01 Cundy Kenneth C. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20090202631A1 (en) * 2002-07-29 2009-08-13 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
US20040254246A1 (en) * 2003-03-31 2004-12-16 Barrett Ronald W. Treating or preventing hot flashes using prodrugs of GABA analogs
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
US20070054945A1 (en) * 2003-08-20 2007-03-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20090234138A1 (en) * 2003-08-20 2009-09-17 Gallop Mark A Acyloxyalkyl carbamate prodrugs, methods
US7572830B2 (en) 2003-08-20 2009-08-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7109239B2 (en) 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20080096960A1 (en) * 2003-08-20 2008-04-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7300956B2 (en) 2003-08-20 2007-11-27 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20050107334A1 (en) * 2003-08-20 2005-05-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20110021571A1 (en) * 2003-08-20 2011-01-27 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20050090550A1 (en) * 2003-09-11 2005-04-28 Barrett Ronald W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
US7700652B2 (en) 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
US20050192353A1 (en) * 2003-09-17 2005-09-01 Barrett Ronald W. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
US8114909B2 (en) 2003-09-17 2012-02-14 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of GABA analogs
WO2005110364A2 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
WO2005110364A3 (en) * 2004-04-30 2006-07-13 Allergan Inc Drug delivery systems and methods for treatment of an eye
US20110201817A1 (en) * 2004-06-04 2011-08-18 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20100197953A9 (en) * 2004-06-04 2010-08-05 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20080132570A1 (en) * 2004-06-04 2008-06-05 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7956212B2 (en) 2004-06-04 2011-06-07 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20080103200A1 (en) * 2004-06-04 2008-05-01 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7671089B2 (en) 2004-06-04 2010-03-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7342131B2 (en) 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US8163958B2 (en) 2004-06-04 2012-04-24 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060020028A1 (en) * 2004-06-04 2006-01-26 Jia-Ning Xiang Levodopa prodrugs, and compositions and uses thereof
US7534813B2 (en) 2004-06-04 2009-05-19 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20090137834A1 (en) * 2004-06-04 2009-05-28 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20050282891A1 (en) * 2004-06-04 2005-12-22 Jia-Ning Xiang Levodopa prodrugs, and compositions and uses thereof
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US20060111325A1 (en) * 2004-11-03 2006-05-25 Gallop Mark A Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US20090124582A1 (en) * 2004-11-03 2009-05-14 Xenoport, Inc. Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use
US20060111439A1 (en) * 2004-11-03 2006-05-25 Gallop Mark A Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20080242723A1 (en) * 2004-11-03 2008-10-02 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7935686B2 (en) 2004-11-03 2011-05-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US20060141034A1 (en) * 2004-11-04 2006-06-29 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US8906412B2 (en) 2004-11-04 2014-12-09 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
US20060205677A1 (en) * 2005-02-23 2006-09-14 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
EP2338881A1 (en) 2005-02-23 2011-06-29 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US7777070B2 (en) 2005-06-20 2010-08-17 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20070027210A1 (en) * 2005-06-20 2007-02-01 Noa Zerangue Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7592369B2 (en) 2005-06-20 2009-09-22 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20110009483A1 (en) * 2005-06-20 2011-01-13 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US8372881B2 (en) 2005-06-20 2013-02-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US8193242B2 (en) 2005-12-05 2012-06-05 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7893105B2 (en) 2005-12-05 2011-02-22 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20070225366A1 (en) * 2005-12-05 2007-09-27 Jia-Ning Xiang Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20110111062A1 (en) * 2005-12-05 2011-05-12 Jia-Ning Xiang Levodopa prodrug mesylate, compositions thereof, and uses thereof
US20090156679A1 (en) * 2005-12-05 2009-06-18 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7968597B2 (en) 2005-12-05 2011-06-28 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US8216603B2 (en) 2006-05-04 2012-07-10 Herbert Edward Kaufman Method, device, and system for delivery of therapeutic agents to the eye
US20090220573A1 (en) * 2006-05-04 2009-09-03 Herbert Edward Kaufman Method, Device, and System for Delivery of Therapeutic Agents to the Eye
JP4829345B2 (en) * 2006-05-04 2011-12-07 カフマン、ハーバート Method for administering a therapeutic agent to the eye, apparatus, and systems
WO2007130663A3 (en) * 2006-05-04 2008-11-13 Herbert Kaufman Method, device, and system for delivery of therapeutic agents to the eye
US8668920B2 (en) * 2006-05-04 2014-03-11 Hek Development, Llc Method, device, and system for delivery of therapeutic agents to the eye
EP2402037A1 (en) 2006-05-26 2012-01-04 Pharmacofore, Inc. Controlled release of phenolic opioids
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080085306A1 (en) * 2006-08-31 2008-04-10 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US7749985B2 (en) 2006-09-15 2010-07-06 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20090286759A1 (en) * 2006-09-15 2009-11-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US7585996B2 (en) 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20080146526A1 (en) * 2006-09-15 2008-06-19 Gallop Mark A Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US8663683B2 (en) 2006-11-17 2014-03-04 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US9549940B2 (en) 2006-11-17 2017-01-24 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US9555004B2 (en) 2006-11-17 2017-01-31 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US9622983B2 (en) 2006-11-17 2017-04-18 Supernus Pharmaceutcals, Inc. Sustained-release formulations of topiramate
US8889191B2 (en) 2006-11-17 2014-11-18 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US8298580B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US8992989B2 (en) 2006-11-17 2015-03-31 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20080118557A1 (en) * 2006-11-17 2008-05-22 Supernus Pharnaceuticals, Inc. Sustained-release formulations of topiramate
US8877248B1 (en) 2006-11-17 2014-11-04 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20080161393A1 (en) * 2006-12-08 2008-07-03 Barrett Ronald W Use of prodrugs of GABA analogs for treating disease
US20080214663A1 (en) * 2006-12-21 2008-09-04 Jia-Ning Xiang Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US20080171789A1 (en) * 2006-12-21 2008-07-17 Jia-Ning Xiang Catechol protected levodopa diester prodrugs, compositions, and methods of use
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US8324273B2 (en) 2006-12-21 2012-12-04 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20110028544A1 (en) * 2006-12-21 2011-02-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US8324272B2 (en) 2006-12-21 2012-12-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US20100099907A1 (en) * 2008-10-20 2010-04-22 Xenoport, Inc. Methods of Synthesizing a Levodopa Ester Prodrug
US8722733B2 (en) 2008-10-20 2014-05-13 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US20100099761A1 (en) * 2008-10-20 2010-04-22 Xenoport, Inc. Levodopa Prodrug Mesylate Hydrate
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9937073B2 (en) 2015-01-20 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Similar Documents

Publication Publication Date Title
US3626940A (en) Ocular insert
Zimmer et al. Microspheres and nanoparticles used in ocular delivery systems
US3630200A (en) Ocular insert
US4478818A (en) Ocular preparation housing steroid in two different therapeutic forms
Yasukawa et al. Intraocular sustained drug delivery using implantable polymeric devices
US6159491A (en) Prolonged release bioadhesive vaginal gel dosage form
US4713244A (en) Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4693887A (en) Microphase separated hydrogels for controlled release of bioactive materials
Colthurst et al. Biomaterials used in the posterior segment of the eye
US6063396A (en) Methods and compositions for the modulation of cell proliferation and wound healing
US5147647A (en) Ocular insert for the fornix
US5766619A (en) Pharmaceutical dosage form for ocular administration and preparation process
US3961628A (en) Ocular drug dispensing system
US5395618A (en) Ocular insert with anchoring protrusions
US5766242A (en) Biocompatible ocular implants
US5707643A (en) Biodegradable scleral plug
US7204995B2 (en) Treatment and control of dry eye by use of biodegradable polymer capsules
US4304765A (en) Ocular insert housing steroid in two different therapeutic forms
Ludwig The use of mucoadhesive polymers in ocular drug delivery
US20090264813A1 (en) Apparatus and methods for implanting particulate ocular implants
US7993634B2 (en) Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
EP0430539B1 (en) Ocular implants
US5618553A (en) Methods and compositions for the modulation of cell proliferation and wound healing
US4281654A (en) Drug delivery system for controlled ocular therapy
US3995635A (en) Ocular insert